← All State Street CORP filings

State Street CORP Schedule 13G passive stakes

NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 7.4% Stake in Astronix Corp
State Street Corporation and its affiliate SSGA Funds Management, Inc. have reported beneficial ownership of 7.4% of Astronix Corp's common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.5% Stake in Ardaelyx
State Street Corporation has reported a beneficial ownership of 5.5% of Ardaelyx Inc.'s common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.1% Stake in Arcutis Biotherapeutics
State Street Corporation has reported beneficial ownership of 5.1% of Arcutis Biotherapeutics Inc.'s common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.4% Stake in Apellis Pharmaceuticals
State Street Corporation has reported beneficial ownership of 5.4% of Apellis Pharmaceuticals Inc. common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.1% Stake in Ameriprise Financial
State Street Corporation has reported beneficial ownership of 5.1% of Ameriprise Financial Inc.'s common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.1% Stake in American Healthcare REIT
State Street Corporation has reported beneficial ownership of 5.1% of American Healthcare REIT Inc.'s common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 7.6% Stake in American Battery Technology
State Street Corporation and SSGA Funds Management, Inc. have reported beneficial ownership of 7.6% of American Battery Technology Co.'s common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 6.3% Stake in Amcor PLC
State Street Corporation has reported beneficial ownership of 29,214,378 shares, representing 6.3% of Amcor PLC's common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.5% Stake in Altimmune
State Street Corporation has reported beneficial ownership of 5.5% of Altimmune Inc.'s common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Akebia Therapeutics Stake
State Street Corporation has reported beneficial ownership of 4.3% of Akebia Therapeutics Inc. common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Agree Realty Stake
State Street Corporation has reported a significant beneficial ownership stake in Agree Realty Corp., holding 5,967,031 shares, representing 5% of the class.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 6.5% Stake in AAR Corp
State Street Corporation has reported beneficial ownership of 2,587,621 shares, representing 6.5% of the outstanding common stock of AAR Corp.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.3% Stake in 4D Molecular Therapeutics
State Street Corporation has reported beneficial ownership of 5.3% of 4D Molecular Therapeutics' common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: Vanguard Discloses Stake in State Street Corp
Vanguard Capital Management reports beneficial ownership of 20,493,476 shares, representing 7.35% of State Street Corp's common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: Vanguard Portfolio Management Discloses State Street Stake
Vanguard Portfolio Management has reported beneficial ownership of 5.8% of State Street Corp. common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Stake in Trade Desk
State Street Corporation and its subsidiary SSGA Funds Management, Inc. have reported beneficial ownership of 10.4% and 7.2% of Trade Desk's common stock, respectively, as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Significant Stake in News Corp
State Street Corporation and its affiliate SSGA Funds Management, Inc. have reported beneficial ownership of over 10.6% of News Corp's common stock as of March 31, 2026.
NYSE
STT
State Street CORP
SCHEDULE: Vanguard Group Amends State Street Corp Ownership to Zero
The Vanguard Group has filed an amendment to its Schedule 13G for State Street Corp, reporting zero beneficial ownership following an internal realignment.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 6.3% Stake in Xencor Inc.
State Street Corporation has reported a 6.3% beneficial ownership stake in Xencor Inc. common stock as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.3% Stake in Warner Bros Discovery
State Street Corporation has reported a 5.3% beneficial ownership stake in Warner Bros Discovery Inc., holding over 131 million shares as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 9% Stake in Vuzix Corp
State Street Corporation and its subsidiary SSGA Funds Management, Inc. have disclosed beneficial ownership of 9% of Vuzix Corp's common stock as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 4.9% Stake in Veris Residential
State Street Corporation has reported a 4.9% beneficial ownership stake in Veris Residential Inc. as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.5% Stake in US Antimony Corp
State Street Corporation has reported a passive beneficial ownership of 5.5% in United States Antimony Corp, holding 7,669,026 common shares.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.2% Stake in UNIQURE NV
State Street Corporation has filed a Schedule 13G, reporting a 5.2% beneficial ownership stake in UNIQURE NV as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.3% Stake in Travere Therapeutics
State Street Corporation has reported a 5.3% beneficial ownership stake in Travere Therapeutics Inc. common stock as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 7.1% Stake in The Trade Desk
State Street Corporation has reported a 7.1% beneficial ownership stake in The Trade Desk Inc. common stock as of December 31, 2025.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.3% Stake in Syndax Pharma
State Street Corporation has reported a 5.3% beneficial ownership stake in Syndax Pharmaceuticals Inc., holding 4,596,552 common shares.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 4.9% Stake in STAG Industrial
State Street Corporation has reported a 4.9% beneficial ownership stake in STAG Industrial Inc., holding over 9.1 million shares of common stock.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 5.2% Passive Stake in Simmons First
State Street Corporation has reported a 5.2% passive beneficial ownership stake in Simmons First National Corp, holding over 7.5 million shares.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 4.7% Stake in Seacoast Banking
State Street Corporation has reported a 4.7% beneficial ownership stake in Seacoast Banking Corp of Florida as of December 31, 2025.